Beaumont Hospital

Futó vizsgálatok

• Még nem toboroz

  Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis

  2025-523400-72-00· 2. fázis· Forrás

• Toboroz

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· 3. fázis· Forrás

• Toboroz

  Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC

  NCT07158489· 2. fázis· Forrás

• Toboroz

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· 3. fázis· Forrás

• Még nem toboroz

  HOVON 168:Study on epcoritamab in frail patients with diffuse large B-Cell lymphoma (DLBCL) who have not been treated before

  2025-524230-25-00· 2. fázis· Forrás

• Toboroz

  Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS (PREVAiLS)

  2025-524002-16-00· 3. fázis· Forrás

• Toboroz

  A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)

  NCT07221669· 3. fázis· Forrás

• Toboroz

  A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis

  2025-521546-23-00· 3. fázis· Forrás

• Toboroz

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· 3. fázis· Forrás

• Toboroz

  A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma

  NCT07456033· 3. fázis· Forrás

• Toboroz

  Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)

  NCT07223814· 3. fázis· Forrás

• Toboroz

  A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy

  NCT06931717· 3. fázis· Forrás

• Toboroz

  A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

  NCT06932562· 3. fázis· Forrás

• Toboroz

  Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

  NCT07023835· 2. fázis· Forrás

• Toboroz

  Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

  NCT06982521· 3. fázis· Forrás

• Toboroz

  A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

  NCT06863272· 1/2. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab

  NCT06880744· 3. fázis· Forrás

• Toboroz

  A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated chronic lymphocytic leukaemia (CLL)/ small lymphocytic lymphoma (SLL) aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes (CLL18/ MOIRAI)

  2023-510294-34-00· 3. fázis· Forrás

• Toboroz

  Intermittent Androgen Deprivation Therapy in the Era of AR Pathway Inhibitors

  NCT05974774· 3. fázis· Forrás

• Toboroz

  A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

  NCT06499285· 3. fázis· Forrás

• Toboroz

  Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  NCT06881784· 3. fázis· Forrás

• Toboroz

  Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  NCT06652438· 3. fázis· Forrás

• Toboroz

  A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  NCT06875310· 3. fázis· Forrás

• Toboroz

  A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  NCT06890884· 2. fázis· Forrás

• Toboroz

  A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  NCT06868277· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer

  NCT06764485· 3. fázis· Forrás

• Toboroz

  An Adaptive, Dose-Ranging, Phase 2 Study of Eltrekibart Given Alone or in Combination with Mirikizumab for the Treatment of Adult Patients with Moderately to Severely Active Ulcerative Colitis

  2023-507853-13-00· 2. fázis· Forrás

• Toboroz

  FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC

  NCT06788990· 2/3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

  NCT06284317· 3. fázis· Forrás

• Fut, nem toboroz

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· 3. fázis· Forrás

• Toboroz

  A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

  NCT06227910· 3. fázis· Forrás

• Fut, nem toboroz

  Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over Standard of Care Docetaxel in Non-Small Cell Lung Cancer (ABBIL1TY NSCLC-06)

  NCT06635824· 3. fázis· Forrás

• Fut, nem toboroz

  A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

  NCT06643481· 2. fázis· Forrás

• Toboroz

  Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

  NCT06548542· 2. fázis· Forrás

• Fut, nem toboroz

  A Study of Ocular Toxicity Evaluation and Mitigation During Treatment With Mirvetuximab Soravtansine in Participants With Recurrent Ovarian Cancer With High Folate Receptor-Alpha Expression

  NCT06365853· 2. fázis· Forrás

• Fut, nem toboroz

  A Study Comparing Niraparib With Temozolomide in Adult Participants With Newly-diagnosed, MGMT Unmethylated Glioblastoma

  NCT06388733· 3. fázis· Forrás

• Toboroz

  A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer

  NCT06320067· 3. fázis· Forrás

• Toboroz

  Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

  NCT05950945· 3. fázis· Forrás

• Fut, nem toboroz

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· 3. fázis· Forrás

• Fut, nem toboroz

  Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2

  NCT05911295· 3. fázis· Forrás

• Toboroz

  Tranexamic acid for hyperacute spontaneous IntraCerebral Haemorrhage (TICH-3)

  2022-500587-35-01· 3. fázis· Forrás

• Meghívásos bevonás

  An Open-label Study of XEN1101 in Epilepsy

  NCT05718817· 3. fázis· Forrás

• Fut, nem toboroz

  A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery

  NCT05608291· 3. fázis· Forrás

• Fut, nem toboroz

  ABTECT - Maintenance

  NCT05535946· 3. fázis· Forrás

• Toboroz

  Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

  NCT05633654· 3. fázis· Forrás

• Fut, nem toboroz

  Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

  NCT05407324· 2. fázis· Forrás

• Toboroz

  A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

  NCT05253651· 3. fázis· Forrás

• Fut, nem toboroz

  A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

  NCT05450692· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

  NCT05243797· 3. fázis· Forrás

Egyszerre toboroz

Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.

• Tüdőrák10 toboroz
• Akut mieloid leukémia (AML)2 toboroz
• Amiotrófiás laterálszklerózis (ALS)2 toboroz
• Crohn-betegség2 toboroz
• Diffúz nagy B-sejtes limfóma (DLBCL)2 toboroz
• Prosztatarák2 toboroz
• Vastagbélrák2 toboroz
• Asztma1 toboroz
• Áttétes emlőrák1 toboroz
• Cisztás fibrózis1 toboroz
• Fej-nyaki daganatok1 toboroz
• Glioblasztóma1 toboroz
• Huntington-kór1 toboroz
• Krónikus limfoid leukémia (CLL)1 toboroz
• Mielodiszplasztikus szindróma (MDS)1 toboroz
• Mielóma multiplex1 toboroz
• Sclerosis multiplex (SM)1 toboroz
• Spinális izomatrófia (SMA)1 toboroz
• Stroke (szélütés)1 toboroz
• Tripla negatív emlőrák1 toboroz

Kutatók

Ide még nem kötődik kutató.

Lezárt vizsgálatok

• Toboroz

  A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008)

  2024-518296-56-00· 3. fázis· Forrás

• Fut, nem toboroz

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· 3. fázis· Forrás

• Lezárult

  A Phase 2 Study to Investigate Efficacy and Safety of HZN-1116 in Participants With Sjögren’s Syndrome

  NCT06312020· 2. fázis· Forrás

• Fut, nem toboroz

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· 2. fázis· Forrás

• Fut, nem toboroz

  A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma

  NCT06190951· 2. fázis· Forrás

• Lezárult

  A Study designed to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo plus atezolizumab administered in participants with PD-L1 ≥ 1% TC Stage IIB, IIIA, or select IIIB (T3N2 only) NSCLC following resection and adjuvant platinum-based chemotherapy

  2023-506696-10-00· 3. fázis· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab

  NCT06211036· 3. fázis· Forrás

• Toboroz

  A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

  NCT06430801· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Assess Adverse Events and Change in Disease Activity From Intravenous (IV) and Subcutaneous (SC) Lutikizumab in Adult Participants With Active Ulcerative Colitis

  NCT06257875· 2. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy

  NCT05979311· 3. fázis· Forrás

• Fut, nem toboroz

  Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status

  NCT05673187· 2. fázis· Forrás

• Fut, nem toboroz

  Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer

  NCT05740566· 3. fázis· Forrás

• Lezárult

  A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Assess the Efficacy, Safety, Tolerability, PK, and Biomarker Effects of PTC857 in Adult Subjects With Amyotrophic Lateral Sclerosis (CARDINALS)

  NCT05349721· 2. fázis· Forrás

• Lezárult

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· 3. fázis· Forrás

• Lezárult

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· 3. fázis· Forrás

• Fut, nem toboroz

  Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer

  NCT05456685· 2. fázis· Forrás

• Fut, nem toboroz

  Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)

  NCT05224141· 3. fázis· Forrás

• Lezárult

  Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma

  NCT05064358· 2. fázis· Forrás

• Fut, nem toboroz

  CPD-DARA in Patients With Relapsed/Refractory Multiple Myeloma.

  NCT04667663· 1. fázis· Forrás

• Lezárult

  A study to investigate the safety and efficacy of AMX0035 in patients with Amyotrophic Lateral Sclerosis

  NCT05021536· 3. fázis· Forrás

• Lezárult

  A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis

  NCT04973137· 3. fázis· Forrás

• Lezárult

  Lighthouse II study

  NCT05193994· 3. fázis· Forrás

• Fut, nem toboroz

  A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

  NCT04736706· 3. fázis· Forrás

• Fut, nem toboroz

  Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

  NCT04685135· 3. fázis· Forrás

• Lezárult

  A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)

  NCT04623775· 2. fázis· Forrás

• Lezárult

  Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer

  NCT04736173· 2. fázis· Forrás

• Lezárult

  Phase 3 Study of Pembrolizumab/Placebo plus Enzalutamide plus ADT in mHSPC

  NCT04191096· 3. fázis· Forrás

• Lezárult

  A Prospective Phase III Multi-center, 2-Year Placebo Controlled, Double Blind Study to Evaluate the Efficacy and Safety of "Kamada-AAT for Inhalation" 80 mg per day in Adult Patients with Congenital Alpha-1 Antitrypsin Deficiency with Moderate and Severe Airflow Limitation (40% ≤ FEV1 ≤ 80% of predicted; FEV1/SVC ≤ 70%), Followed by a 2-Year Open-Label Extension

  NCT04204252· 3. fázis· Forrás

• Fut, nem toboroz

  An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

  NCT03844048· 3. fázis· Forrás

• Lezárult

  Phase 3 Study of Pembrolizumab plus Enzalutamide in mCRPC

  NCT03834493· 3. fázis· Forrás

• Lezárult

  Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)

  NCT03615326· 3. fázis· Forrás

• Lezárult

  Multicenter Extension Study of Oral Ozanimod in patients with Moderately to Severely Active Crohn's Disease

  2024-511553-22-00· 3. fázis· Forrás

• Lezárult

  Multicenter Study of Oral Ozanimod as Maintenance Therapy in patients with Moderately to Severely Active Crohn's Disease

  2023-510426-33-00· 3. fázis· Forrás

• Lezárult

  Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer

  NCT03409614· 3. fázis· Forrás

• Fut, nem toboroz

  A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)

  NCT03006068· 3. fázis· Forrás

• Lezárult

  A study of nivolumab or placebo in patients following removal of their esophageal or gastroesophageal junction cancer.

  NCT02743494· 3. fázis· Forrás